Paliperidone Palmitate for Schizophrenia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Paliperidone palmitate, a long-acting intramuscular formulation of paliperidone, is now available for clinical use. Paliperidone is an active metabolite of risperidone, and it is also available in an oral formulation for daily use. To compare effects of paliperidone palmitate with any other treatment for people with schizophrenia and schizophrenia-like illnesses.1 We searched the Cochrane Schizophrenia Group’s Register (November 2009) and inspected references of identified studies for further trials. We contacted the manufacturers of paliperidone palmitate, the Food and Drug Administration, and authors of relevant trials for additional material. We included all relevant randomized controlled trials (RCTs). We independently selected and critically appraised studies, extracted data and analyzed on an intention-to-treat basis. Where possible and appropriate, we calculated risk ratios (RRs) and their 95% confidence intervals (CIs) with the number needed to benefit/harm statistic (NNB/H). We calculated weighted mean differences (MD) for continuous data. Five studies with 2 215 participants compared paliperidone palmitate with placebo. Fewer people left studies early if they were randomized to paliperidone palmitate (n = 2 183, 5 RCTs, RR 0.76 CI 0.70–0.84, NNTB 9 CI 7–14) and those receiving any dose of paliperidone palmitate were significantly less likely to show no improvement in global state (n = 1696, 4 RCTs, RR 0.79 CI 0.74–0.85, NNTB 7 CI 5–9). People randomized to paliperidone palmitate were less likely to experience a recurrence of psychosis (n = 312, 1 RCT, RR 0.28 CI 0.17–0.48, NNTB 5 CI 4–6) than those allocated to placebo in a single trial specifically designed to study recurrence. In the other studies where recurrence was recorded only as an adverse event, we found that people who received paliperidone palmitate were also less likely to experience a recurrence of psychotic symptoms (n = 1 837, 4 RCTs, RR 0.55 CI 0.44–0.68, NNTB 10 CI 8–14). Paliperidone palmitate was associated with fewer reports of agitation or aggression (n = 2 180, 5 RCTs, RR 0.65 CI 0.46–0.91, NNTB 39 CI 25–150) and of using anxiolytic medications (n = 2 170, 5 RCTs, RR 0.89 CI 0.83–0.96, NNTB 16 CI 11–44). A consistent, significant elevation in serum prolactin (ng/mL) was found for both men and women receiving paliperidone palmitate, but the data was too heterogenous to sum. We found no evidence of sexual dysfunction in these short-term trials. People receiving paliperidone palmitate had a significantly greater increase in weight (n = 2 052, 5 RCTs, WMD 1.34 CI 0.97 to 1.70) in comparison with people who received placebo. Two studies with 1 969 participants compared flexibly-dosed paliperidone palmitate with flexibly dosed risperidone long-acting injection. The mean doses of paliperidone palmitate in these trials were 73.3 and 104.6mg every 4 weeks compared with risperidone long-acting injection at mean doses, respectively, of 35.3 and 31.7mg every 2 weeks. We found no differences between paliperidone palmitate and risperidone long-acting injection for leaving these studies early for any reason (n = 1 969, 2 RCTs, RR 1.12 CI 1.00–1.25). Those receiving paliperidone palmitate were statistically no more likely to have a recurrence of psychotic symptoms than those receiving risperidone LAI (n = 1961, 2 RCTs, RR 1.23 CI 0.98–1.53). Although we found no significant difference in the occurrences of deaths in the pooled trials (n = 1 967, 2 RCTs, RR 3.62 CI 0.60–21.89), we note that a total of six deaths occurred in these two trials, with five deaths among people who received paliperidone palmitate and one death among people who received risperidone long-acting injection. Although death is the most serious of adverse events, the small number of these events in these trials makes it unclear if this finding is meaningful. We found that subjects randomized to paliperidone palmitate were significantly less likely to use anticholinergic medications in these trials (n = 1 587, 2 RCTs, RR 0.67 CI 0.55–0.82, NNTB 13 CI 10–24). We found no data regarding paliperidone palmitate relating to services use, quality of life, patient satisfaction, or cost. In short-term studies, paliperidone palmitate is an antipsychotic drug that is more efficacious than placebo. We found its adverse effects to be similar to those of its related compounds, paliperidone and risperidone, with extrapyramidal movement disorders, weight gain, and tachycardia all more common with paliperidone palmitate than placebo. Although no difference was found in the incidence of reported adverse sexual outcomes, paliperidone palmitate is associated with substantial increases in serum prolactin. When flexibly dosed with mean doses of approximately 70–110mg every 4 weeks, paliperidone palmitate appears comparable in efficacy and tolerability to risperidone long-acting injection flexibly dosed with mean doses of approximately 35mg every 2 weeks. Leaving the study early for any reason.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationMoher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Statistics Notes: Detecting skewness from summary information: Table 1
Altman, D. G., & Bland, J. M. (1996) · BMJ · doi:10.1136/bmj.313.7066.1200 · Cited by 1,278
Marshall, M., Lockwood, A., Bradley, C., Adams, C., Joy, C., & Fenton, M. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.3.249 · Cited by 870
The unit of analysis error in studies about physicians' patient care behavior
Divine, G. W., Brown, J. T., & Frazier, L. M. (1992) · Journal of General Internal Medicine · doi:10.1007/bf02599201 · Cited by 749
Issues in the meta-analysis of cluster randomized trials
Donner, A., & Klar, N. (2002) · Statistics in Medicine · doi:10.1002/sim.1301 · Cited by 734
Samtani, M. N., Vermeulen, A., & Stuyckens, K. (2009) · Clinical Pharmacokinetics · doi:10.2165/11316870-000000000-00000 · Cited by 170
Cited by
An update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135
Metadata
- Authors
- Nussbaum, A. M., & Stroup, T. S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-10
- Volume
- 38
- Issue
- 6
- Pages
- 1124-1127
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2144173860
- Cited by
- 210
- References
- 9
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.